Bristol-Myers Squibb CompanyNew Longer-Term Data for Empliciti Showed Continued Progression-Free Survival Benefit in Patients with Relapsed or Refractory Multiple Myeloma #ASH2015
December 05, 2015 at 10:27 AM EST
Bristol-Myers Squibb Company (NYSE: BMY) today presented extended follow-up data and a pre-specified interim ...
